Assessing ICON (ICLR) Valuation After 2025 Results And New 2026 Revenue Guidance

Simply Wall St.06-11

ICON (ICLR) is back in focus after issuing 2026 revenue guidance of US$7.85b to US$8.15b, alongside fourth quarter and full year 2025 results that showed lower earnings despite slightly higher sales. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642473825?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-06-11 01:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642473825","market":"sg","top_or_hot":-1,"title":"Assessing ICON (ICLR) Valuation After 2025 Results And New 2026 Revenue Guidance","media":"Simply Wall St.","content":"<div>\n<p>ICON (ICLR) is back in focus after issuing 2026 revenue guidance of US$7.85b to US$8.15b, alongside fourth quarter and full year 2025 results that showed lower earnings despite slightly higher sales. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/assessing-icon-iclr-valuation-after-2025-results-and-new-202\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing ICON (ICLR) Valuation After 2025 Results And New 2026 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing ICON (ICLR) Valuation After 2025 Results And New 2026 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 01:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/assessing-icon-iclr-valuation-after-2025-results-and-new-202><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ICON (ICLR) is back in focus after issuing 2026 revenue guidance of US$7.85b to US$8.15b, alongside fourth quarter and full year 2025 results that showed lower earnings despite slightly higher sales. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/assessing-icon-iclr-valuation-after-2025-results-and-new-202\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICLR","symbol_name":"ICON plc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/assessing-icon-iclr-valuation-after-2025-results-and-new-202","article_id":"2642473825","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/assessing-icon-iclr-valuation-after-2025-results-and-new-202","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642473825","pubTimestamp":1781112190,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ICON (ICLR) is back in focus after issuing 2026 revenue guidance of US$7.85b to US$8.15b, alongside fourth quarter and full year 2025 results that showed lower earnings despite slightly higher sales.\nSee our latest analysis for ICON.\nThe earnings update and new 2026 guidance have arrived after a sharp rebound in the stock, with a 30 day share price return of 21.95% and a 90 day gain of 44.07%. However, longer term total shareholder returns over three and five years remain negative, so recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICLR":"ICON plc","ICON":"Icon Energy Corp."},"translate_title":"评估2025年业绩和新的2026年收入指引后的ICON(ICLR)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICLR":1.5,"ICON":1.5},"content_text":"ICON (ICLR) is back in focus after issuing 2026 revenue guidance of US$7.85b to US$8.15b, alongside fourth quarter and full year 2025 results that showed lower earnings despite slightly higher sales. See our latest analysis for ICON. The earnings update and new 2026 guidance have arrived after a sharp rebound in the stock, with a 30 day share price return of 21.95% and a 90 day gain of 44.07%. However, longer term total shareholder returns over three and five years remain negative, so recent momentum is building off a weaker base. If you are looking beyond ICON to see where capital is moving in healthcare, this is a useful moment to scan 39 healthcare AI stocks for potential new ideas. With ICON trading close to analyst price targets but still showing an intrinsic value gap, the key question is simple: after this earnings reset, is there still a buying opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 12.4% Overvalued ICON’s most followed valuation narrative pegs fair value at $135.07, which sits below the last close at $151.82 and frames the recent rebound as rich against those assumptions.  The analysts have a consensus price target of $135.07 for ICON based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $180.0, and the most bearish reporting a price target of just $90.0.  Read the complete narrative. The narrative rests on a tight mix of modest revenue growth, slightly higher margins and a future earnings multiple that has to do some heavy lifting. Want to see how those moving parts combine into a single fair value line, and which assumptions matter most if they shift even slightly? Result: Fair Value of $135.07 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still meaningful risks, including the internal accounting investigation and elevated clinical trial cancellations, which could easily unsettle this valuation story. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Another View: Cash Flows Point to a Different Story While analyst targets suggest ICON is 12.4% overvalued at $151.82 versus a $135.07 fair value, Simply Wall St’s DCF model points the other way. On that framework, ICON trades at $151.82 against an estimated future cash flow value of $244.51, which implies a wide valuation gap. Which set of assumptions do you trust more when the signals disagree this much? Look into how the SWS DCF model arrives at its fair value. ICLR Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ICON for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With the story pulling in both directions, do you feel ICON still fits your thesis, or is sentiment getting ahead of itself? Act while the details are fresh in mind and stress test your own view by weighing the 2 key rewards and 2 important warning signs Looking for more investment ideas? If ICON feels fully priced to you right now, do not stop here. Broaden your watchlist with other stocks that could fit your risk and return preferences.  Hunt for potential mispriced opportunities by scanning 46 high quality undervalued stocks that line up strong fundamentals with market skepticism. Build a steadier income stream by reviewing 9 dividend fortresses that combine higher yields with balance sheet resilience. Sleep easier at night by filtering for 63 resilient stocks with low risk scores that aim to keep volatility and financial stress in check.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642473825","isCrawlerRequest":true}